Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
24 hedge funds and large institutions have $5.94M invested in Acura Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
9% more funds holding
Funds holding: 22 → 24 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $7.14M → $5.94M (-$1.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$54K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.6K |
| 3 |
Renaissance Technologies
New York
|
+$11.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.07K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$80 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$293K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$38K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.68K |
| 5 |
Morgan Stanley
New York
|
-$28 |
ACUR Hedge Fund Activity: Q3 2016 in Review
24 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q3 2016, worth a combined $5.94M — down 17% from $7.14M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ACUR positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $54K. The largest seller was Sabby Management, cutting an estimated $293K.
- 24 institutional investors held Acura Pharmaceuticals (ACUR) as of Q3 2016, up from 22 in Q2 2016.
- Funds reported $5.94M of Acura Pharmaceuticals stock for Q3 2016, down 17% quarter-over-quarter.
- 3 funds opened new Acura Pharmaceuticals positions in Q3 2016 and 1 closed out, a net change of +2 holders.
- The largest Acura Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $54K added.
- The largest Acura Pharmaceuticals seller in Q3 2016 was Sabby Management, an estimated $293K sold.
Based on aggregated 13F filings for Q3 2016.